IL162602D0 - Pyrrolidine derivatives as prostaglandin modulators - Google Patents
Pyrrolidine derivatives as prostaglandin modulatorsInfo
- Publication number
- IL162602D0 IL162602D0 IL16260202A IL16260202A IL162602D0 IL 162602 D0 IL162602 D0 IL 162602D0 IL 16260202 A IL16260202 A IL 16260202A IL 16260202 A IL16260202 A IL 16260202A IL 162602 D0 IL162602 D0 IL 162602D0
- Authority
- IL
- Israel
- Prior art keywords
- pyrrolidine derivatives
- prostaglandin modulators
- prostaglandin
- modulators
- pyrrolidine
- Prior art date
Links
- 230000000051 modifying Effects 0 title 1
- 150000003180 prostaglandins Chemical class 0 title 1
- 150000003235 pyrrolidines Chemical class 0 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with heteroatoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34262001P true | 2001-12-20 | 2001-12-20 | |
| PCT/EP2002/014593 WO2003053923A2 (en) | 2001-12-20 | 2002-12-19 | Pyrrolidine derivatives as prostaglandin modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL162602D0 true IL162602D0 (en) | 2005-11-20 |
Family
ID=23342570
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16260202A IL162602D0 (en) | 2001-12-20 | 2002-12-19 | Pyrrolidine derivatives as prostaglandin modulators |
| IL16260204A IL162602A (en) | 2001-12-20 | 2004-06-17 | Pyrrolidine derivatives as prostaglandin modulators |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16260204A IL162602A (en) | 2001-12-20 | 2004-06-17 | Pyrrolidine derivatives as prostaglandin modulators |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7335680B2 (en) |
| EP (1) | EP1458679B1 (en) |
| JP (1) | JP4554931B2 (en) |
| AT (1) | AT455758T (en) |
| AU (2) | AU2002358772B2 (en) |
| CA (1) | CA2469075C (en) |
| DE (1) | DE60235198D1 (en) |
| ES (1) | ES2337887T3 (en) |
| IL (2) | IL162602D0 (en) |
| WO (1) | WO2003053923A2 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4554931B2 (en) * | 2001-12-20 | 2010-09-29 | メルク セローノ ソシエテ アノニム | Pyrrolidine derivatives as prostaglandin modulators |
| US7547715B2 (en) | 2002-10-10 | 2009-06-16 | Ono Pharmaceutical Co., Ltd. | Endogenous repair factor production accelerator |
| KR100843244B1 (en) | 2007-04-19 | 2008-07-02 | 삼성전자주식회사 | Semiconductor device and method of fabricating the same |
| EP1841733A2 (en) | 2004-11-08 | 2007-10-10 | Allergan, Inc. | Substituted pyrrolidone compounds as prostaglandin ep4 agonists |
| US7893107B2 (en) | 2005-11-30 | 2011-02-22 | Allergan, Inc. | Therapeutic methods using prostaglandin EP4 agonist components |
| US7557095B2 (en) * | 2006-05-12 | 2009-07-07 | Allergan, Inc. | Therapeutic compounds |
| US7550448B2 (en) * | 2006-05-24 | 2009-06-23 | Allergan, Inc. | Therapeutic compounds |
| US8507545B2 (en) | 2007-05-08 | 2013-08-13 | National University Corporation, Hamamatsu University School Of Medicine | Cytotoxic T cell activator comprising EP4 agonist |
| EP2155733B1 (en) * | 2007-05-23 | 2012-09-26 | Allergan, Inc. | Cyclic lactams for the treatment of glaucoma or elevated intraocular pressure |
| US7964596B2 (en) | 2008-03-07 | 2011-06-21 | Allergan, Inc. | Therapeutic compounds |
| EP2149552A1 (en) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | 5,6 substituted benzamide derivatives as modulators of EP2 receptors |
| EP2149554A1 (en) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma Aktiengesellschaft | Indolyamides as modulators for an EP2 receptor |
| EP2149551A1 (en) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | N-(indol-3-ylalkyl)-(hetero)arylamid derivatives as modulators of EP2 receptors |
| WO2010052625A1 (en) * | 2008-11-10 | 2010-05-14 | Pfizer Limited | Pyrrolidines |
| US20110287112A1 (en) | 2009-01-30 | 2011-11-24 | Ono Pharmaceutical Co., Ltd. | Prostate cancer progression inhibitor and progression inhibition method |
| TW201326154A (en) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | Novel 2H-indazoles as EP2 receptor antagonists |
| EP2913047B1 (en) | 2012-10-29 | 2019-05-08 | Cardio Incorporated | Pulmonary disease-specific therapeutic agent |
| WO2015056504A1 (en) | 2013-10-15 | 2015-04-23 | 小野薬品工業株式会社 | Drug-eluting stent graft |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2451160A1 (en) * | 1973-10-30 | 1975-05-07 | Du Pont | 3-pyrazolidones and pyrazolidines |
| US3873566A (en) * | 1973-02-28 | 1975-03-25 | Du Pont | 3-Pyrazolidinones and pyrazolidines |
| US3976660A (en) * | 1974-08-15 | 1976-08-24 | E. R. Squibb & Sons, Inc. | Pyrrolidine derivatives |
| DE2527989A1 (en) * | 1975-06-24 | 1977-01-27 | Hoechst Ag | Synthetic prostaglandin analogues - are specific and long acting luteolytics, secretion inhibitors, spasmolytics and antihypertensives |
| US4033989A (en) * | 1975-09-17 | 1977-07-05 | The Upjohn Company | 9-Deoxy-PGF2 Analogs |
| US4003911A (en) * | 1975-09-26 | 1977-01-18 | E. I. Du Pont De Nemours And Company | Selected 3-pyrrolidinones and 2,4-pyrrolidindiones |
| US4090019A (en) | 1976-05-10 | 1978-05-16 | Minnesota Mining And Manufacturing Company | Geminal prostaglandin analogs |
| US4211876A (en) * | 1979-06-13 | 1980-07-08 | E. I. Du Pont De Nemours And Company | 3-Pyrazolidinone carboxamides |
| US4753945A (en) | 1986-02-19 | 1988-06-28 | Eye Research Institute Of Retina Foundation | Stimulation of tear secretion with phosphodiesterase inhibitors |
| US5091431A (en) | 1988-02-08 | 1992-02-25 | Schering Corporation | Phosphodiesterase inhibitors |
| US5010086A (en) | 1990-02-28 | 1991-04-23 | Sterling Drug Inc. | Imidazopyridines, compositions and use |
| GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| GB9119704D0 (en) | 1991-09-14 | 1991-10-30 | Pfizer Ltd | Therapeutic agents |
| GB9121028D0 (en) | 1991-10-03 | 1991-11-13 | Pfizer Ltd | Therapeutic agents |
| GB9126260D0 (en) | 1991-12-11 | 1992-02-12 | Pfizer Ltd | Therapeutic agents |
| GB9213623D0 (en) | 1992-06-26 | 1992-08-12 | Pfizer Ltd | Therapeutic agents |
| GB9218322D0 (en) | 1992-08-28 | 1992-10-14 | Pfizer Ltd | Therapeutic agents |
| US5605814A (en) | 1993-08-31 | 1997-02-25 | Merck Frosst Canada Inc. | DNA encoding human prostaglandin receptor EP2 |
| US6143746A (en) | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
| GB9514160D0 (en) | 1994-07-25 | 1995-09-13 | Zeneca Ltd | Aromatic compounds |
| GB9417532D0 (en) | 1994-08-31 | 1994-10-19 | Zeneca Ltd | Aromatic compounds |
| GB9423911D0 (en) | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
| TW502026B (en) | 1995-06-20 | 2002-09-11 | Zeneca Ltd | Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates |
| TW434240B (en) | 1995-06-20 | 2001-05-16 | Zeneca Ltd | Aromatic compounds, preparation thereof and pharmaceutical composition comprising same |
| US5834468A (en) | 1995-07-07 | 1998-11-10 | Zeneca Limited | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists |
| GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| GB9514473D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
| GB9514465D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
| KR20000010918A (en) | 1996-05-10 | 2000-02-25 | 게리 엘. 윌콕스 | Carboline derivative |
| US6043252A (en) | 1997-05-05 | 2000-03-28 | Icos Corporation | Carboline derivatives |
| AU5320698A (en) | 1996-11-20 | 1998-06-10 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Substituted dihydrobenzofurans as pde inhibitors |
| TR199901366T2 (en) | 1996-12-20 | 1999-09-21 | Pfizer Inc. | Prevention / repair of bone mass loss with prostaglandin agonists. |
| AT404730B (en) * | 1997-04-07 | 1999-02-25 | Holderchem Ag | Acrylic copolymers and polymer compositions, as well as building materials to their use as additives or admixtures to improve the properties of dispersions, and |
| DK1000035T3 (en) | 1997-07-25 | 2003-03-17 | Altana Pharma Ag | Substituted 6-phenylphenanthridines |
| US6006735A (en) | 1997-09-12 | 1999-12-28 | Park Industries, Inc. | Automated stoneworking system and method |
| US6156753A (en) | 1997-10-28 | 2000-12-05 | Vivus, Inc. | Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| US6127363A (en) | 1997-10-28 | 2000-10-03 | Vivus, Inc. | Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| GB9725953D0 (en) | 1997-12-08 | 1998-02-04 | Pfizer Ltd | Compounds useful in therapy |
| US6211197B1 (en) | 1998-10-07 | 2001-04-03 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
| GB9822238D0 (en) | 1998-10-12 | 1998-12-09 | Pfizer Ltd | Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof |
| TR200201643T2 (en) | 1999-12-22 | 2002-11-21 | Pfizer Products Inc. | The EP4 receptor selective agonists for the treatment of osteoporosis. |
| RU2288913C2 (en) * | 2001-07-16 | 2006-12-10 | Ф.Хоффманн-Ля Рош Аг | Prostaglandin analogs, method for their preparing and pharmaceutical composition possessing selective agonistic activity with respect to ep4-receptor |
| JP4554931B2 (en) * | 2001-12-20 | 2010-09-29 | メルク セローノ ソシエテ アノニム | Pyrrolidine derivatives as prostaglandin modulators |
-
2002
- 2002-12-19 JP JP2003554640A patent/JP4554931B2/en not_active Expired - Fee Related
- 2002-12-19 AT AT02793091T patent/AT455758T/en not_active IP Right Cessation
- 2002-12-19 ES ES02793091T patent/ES2337887T3/en active Active
- 2002-12-19 AU AU2002358772A patent/AU2002358772B2/en not_active Ceased
- 2002-12-19 CA CA 2469075 patent/CA2469075C/en not_active Expired - Fee Related
- 2002-12-19 DE DE2002635198 patent/DE60235198D1/en active Active
- 2002-12-19 IL IL16260202A patent/IL162602D0/en unknown
- 2002-12-19 WO PCT/EP2002/014593 patent/WO2003053923A2/en active Application Filing
- 2002-12-19 US US10/499,346 patent/US7335680B2/en not_active Expired - Fee Related
- 2002-12-19 EP EP20020793091 patent/EP1458679B1/en active Active
-
2004
- 2004-06-17 IL IL16260204A patent/IL162602A/en not_active IP Right Cessation
-
2007
- 2007-11-21 US US11/943,684 patent/US7635713B2/en not_active Expired - Fee Related
-
2009
- 2009-02-19 AU AU2009200663A patent/AU2009200663B2/en not_active Ceased
- 2009-08-03 US US12/534,292 patent/US8058305B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US8058305B2 (en) | 2011-11-15 |
| US20080114051A1 (en) | 2008-05-15 |
| US7635713B2 (en) | 2009-12-22 |
| JP4554931B2 (en) | 2010-09-29 |
| ES2337887T3 (en) | 2010-04-30 |
| AU2002358772B2 (en) | 2008-11-20 |
| AT455758T (en) | 2010-02-15 |
| EP1458679B1 (en) | 2010-01-20 |
| AU2002358772A1 (en) | 2003-07-09 |
| CA2469075A1 (en) | 2003-07-03 |
| WO2003053923A2 (en) | 2003-07-03 |
| CA2469075C (en) | 2011-09-13 |
| DE60235198D1 (en) | 2010-03-11 |
| IL162602A (en) | 2011-07-31 |
| WO2003053923A3 (en) | 2004-01-29 |
| US20090292000A1 (en) | 2009-11-26 |
| US7335680B2 (en) | 2008-02-26 |
| EP1458679A2 (en) | 2004-09-22 |
| JP2005517665A (en) | 2005-06-16 |
| US20050176800A1 (en) | 2005-08-11 |
| AU2009200663B2 (en) | 2011-09-15 |
| AU2009200663A1 (en) | 2009-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60236206D1 (en) | Spiroazacyclic compounds as monoamin receptor modulators | |
| EG22695A (en) | Novel phenyl-propargylether derivatives | |
| EG25614A (en) | Novel pyrroles derivatives as pharmaceutical agents | |
| DK1526134T3 (en) | Triazolyltropane derivatives as CCR5 modulators | |
| GB0117583D0 (en) | Novel compounds | |
| GB0110901D0 (en) | Novel Compounds | |
| AU2002360508A1 (en) | Substituted hydroxyethylamines | |
| AU2002246855A1 (en) | Novel compounds | |
| AU2002218266A1 (en) | Novel indanylidene compounds | |
| AU2002360083A1 (en) | Mononuclearly filled microcapsules | |
| JP2003144789A5 (en) | ||
| JP2002277803A5 (en) | ||
| AU2001274763A1 (en) | Novel compounds | |
| GB0119172D0 (en) | Phenyl pyrrole derivatives | |
| GB0108800D0 (en) | Novel compounds | |
| HK1086269A1 (en) | 2-iminopyrrolidine derivatives | |
| IL162105D0 (en) | New indole derivatives as factor xainhibitors | |
| AU2002246723A1 (en) | Pyrimidineamines as angiogenesis modulators | |
| AUPQ679400A0 (en) | Microgel synthesis | |
| ZA200309522B (en) | Substituted cyclohexane-1-4diamine derivatives | |
| GB0106247D0 (en) | Improvements relating to supports | |
| AU2003253535A1 (en) | N-4-piperidinyl compounds as ccr5 modulators | |
| GB0105895D0 (en) | Novel compounds | |
| HK1068608A1 (en) | 3-Substituted-4-pyrimidone derivatives | |
| AU2002359122A1 (en) | Novel compounds |